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Abstract
Background: Anthrax had become extremely rare in Europe, but in 2010 an outbreak of anthrax among heroin
users in Scotland increased awareness of contaminated heroin as a source of anthrax. We present the first two
Danish cases of injectional anthrax and discuss the clinical presentations, which included both typical and more
unusual manifestations.
Case presentations: The first patient, a 55-year old man with HIV and hepatitis C virus co-infection, presented with
severe pain in the right thigh and lower abdomen after injecting heroin into the right groin. Computed
tomography and ultrasonographic examination of the abdomen and right thigh showed oedematous thickened
peritoneum, distended oedematous mesentery and subcutaneous oedema of the right thigh. At admission the
patient was afebrile but within 24 hours he progressed to severe septic shock and abdominal compartment
syndrome. Cultures of blood and intraperitoneal fluid grew Bacillus anthracis. The patient was treated with
meropenem, clindamycin, ciprofloxacin and metronidazole. Despite maximum supportive care including mechanical
ventilation, vasopressor treatment and continuous veno-venous hemodiafiltration the patient died on day four.
The second patient, a 39-year old man with chronic hepatitis C virus infection, presented with fever and a swollen
right arm after injecting heroin into his right arm. The arm was swollen from the axilla to the wrist with tense and
discoloured skin. He was initially septic with low blood pressure but responded to crystalloids. During the first week,
swelling progressed and the patient developed massive generalised oedema with a weight gain of 40 kg. When
blood cultures grew Bacillus anthracis antibiotic treatment was changed to meropenem, moxifloxacin and
metronidazole, and on day 7 hydroxycloroquin was added. The patient responded to treatment and was
discharged after 29 days.
Conclusions: These two heroin-associated anthrax cases from Denmark corroborate that heroin contaminated with
anthrax spores may be a continuous source of injectional anthrax across Europe. Clinicians and clinical
microbiologists need to stay vigilant and suspect anthrax in patients with a history of heroin use who present with
soft tissue or generalised infection. Marked swelling of affected soft tissue or unusual intra-abdominal oedema
should strengthen clinical suspicion.
Background
Anthrax, caused by Bacillus anthracis, has traditionally
been known in three clinical entities depending on the
route of entry; cutaneous, gastrointestinal or inhalational
anthrax [1]. Twelve years ago Norwegian colleagues de-
scribed the first case of injectional anthrax associated
with heroin use [2]. A recent outbreak of injectional an-
thrax in Scotland (Dec 2009 - Dec 2010) with more than
80 confirmed and probable cases increased the aware-
ness of this route of infection [3]. This outbreak was also
linked to cases in both Germany and England. Very
recently, new cases in Germany [4] and other European
countries have reinforced the need to suspect anthrax in
heroin drug users presenting with signs of infection.
Injectional anthrax has a variety of clinical presenta-
tions that differ from the three classical clinical presen-
tations. Generally cases do not present with the typical
features of cutaneous anthrax with classical black eschar,
but in most cases with marked soft tissue infection with
oedema [5] and often with severe pain.
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In this article we describe the clinical presentation of
the first two Danish cases of anthrax in intravenous
heroin users, both of which had some features typical of





A 55-year old man known with HIV and hepatitis C co-
infection and methadone maintenance therapy was
admitted with distinct pain and swelling of the right
thigh. The patient also complained about intense pain in
his right lower abdomen, which on examination was
found slightly tense, but not peritoneal. He was afebrile
and the C-reactive protein levels in serum were low.
Initially he denied having taken any intravenous drugs;
later it was revealed that he had injected heroin into the
right femoral vein several times during the preceding
four days.
An ultrasonographic examination of the right leg
performed on suspicion of deep venous thrombosis
(DVT) was inconclusive due to scar tissue around the
femoral vein. There was subcutaneous oedema but no
sign of any abscess. The abdominal ultrasound was simi-
larly inconclusive, although oedema in the bowel walls
was seen. A succeeding computed tomography (CT)
scan showed a picture initially interpreted as large
amounts of ascites or exudate (22–25 Hounsfield Units),
but was later re-evaluated as mucous masses, as seen in
the rare condition pseudomyxoma peritonei. On clinical
suspicion of DVT, the patient received low molecular
heparin. He was not started on any antibiotics.
During the first night in hospital he complained about
abdominal pain. He had pronounced sweating and
tachycardia, which was interpreted mainly as opioid
abstinence, and he received morphine on several
occasions.
Day 2
The following morning the patient, after calling the
nurse due to vomiting and abdominal pain, collapsed in
cardiac arrest with pulseless electrical activity. The
cardiac arrest team arrived and spontaneous circulation
was re-established after 12 minutes. On suspicion of
pulmonary embolus or cerebral insult, a computed
tomography (CT) scan of cerebrum and thorax was
performed, which were both without abnormality. The
patient was started on intravenous antibiotic treatment
with cefuroxime 1500 mg q.8.h and metronidazole 500
mg q.8.h on suspicion of aspiration pneumonia.
He was transferred to the Intensive Care Unit where
he expressed fulminant septic shock with multi-organ
failure needing immediate fluid resuscitation, assisted
ventilation and high doses of noradrenaline. He was
severely hypothermic with a core temperature of 35 de-
grees Celsius, blood pressure 84/52 mmHg and mean ar-
terial pressure of 61 mmHg on noradrenalin infusion of
0.2 microgram per kilogram per minute. His arterial
blood gas analysis showed severe metabolic acidosis, pH
6.99, standard base excess −16, and plasma lactate con-
centration of 10.1 millimoles per litre. He required a
FiO2 of 1.0 to keep PaO2 over 8 kPa. There were no se-
cretions or mucus in the trachea or bronchus and no
pleural effusions, but severe oedema of the lungs on
chest x-ray. The cardiac status was assessed to be nor-
mal using trans-oesophageal echocardiography. The
disseminated intravascular coagulation (DIC)-score was
6 [6]. He had a rigid peritoneal abdomen wall and a
swollen, upper right leg. The abdominal rigidity and
intra-abdominal pressure increased in the following
hours. The swelling of the abdominal wall was moderate,
but the patient had severe abdominal compartment syn-
drome with intra-abdominal pressure of 25 mmHg. A
new computed tomography (CT) scan of the abdomen
was performed which showed increasing masses of
suspected mucus with no signs of ileus or perforation
(Figures 1, 2 and 3). An ultrasound-guided needle aspir-
ation was performed; the ultrasound revealed that the
fluid seen on the CT scan represented thickened
peritoneum and an abnormally distended oedematous
mesentery. There were only insignificant amounts of in-
traperitoneal fluid. Nevertheless, two samples of slightly
milky fluid were extracted and sent for microbiological
analysis. The abdominal surgeon concluded that surgical
intervention was not possible.
Figure 1 CT Abdomen of patient 1, here at kidney–level,
showing the dense mucous masses initially interpreted as
pseudomyxoma peritonei filling the abdominal cavity, making
the individual organs difficult to see. On this second CT-scan
from day 2, the masses are increasingly dense, now measuring
around 50 HU. There are no obvious signs of bowel ischemia.
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The antibiotic regime was changed to meropenem 1g
q.8.h, ciprofloxacin 400 mg q.2.h and metronidazole 500
mg q.8.h. As the patient was anuric, acidotic, had
received large amounts of intravenous crystalloid infu-
sions and seemed vastly over hydrated, continuous veno-
venous hemodiafiltration (CVVHDF) was started.
During the following 12 hours the condition of the pa-
tient slightly improved, with FiO2 decreasing to 0.8 and
the intra-abdominal pressure falling to 14 mmHg. He
regained consciousness and responded to verbal com-
mands (Glasgow Coma Scale 12).
Day 3
After the initial recovery seen after the change of anti-
biotic treatment and commencement of CVVHDF, the
patient’s status again deteriorated as he developed hep-
atic failure, rhabdomyolysis, increasing coagulopathy and
acidosis. He was started on treatment with intravenous
steroids in a last attempt to reverse the rapid progres-
sion of shock.
When blood cultures revealed gram-positive rods the
meropenem and ciprofloxacin dose was increased to 2
gram q.8.h. and 400 mg q.8.h. respectively, and
clindamycin 600 mg q.8.h. was added on suspicion of
Bacillus anthracis infection. The abdominal and ortho-
paedic surgeons were again consulted, but surgical
intervention was declined due to the patient’s unstable
condition and the absence of abscesses.
Day 4
The patient died while on maximum treatment with
ventilator support, vasopressor and CVVHDF.
Patient no. 2
Day 1
A 39-year old man with chronic hepatitis C virus infec-
tion and intravenous usage of heroin presented at the
Emergency department with a swollen right arm and
fever. At admission the blood pressure was 77/44
mmHg, pulse 110 beats/min, temperature 39.3°C and ar-
terial oxygen saturation 96 %. He was somnolent. The
right arm was swollen from the axillary region to the
wrist and the skin was tense and discoloured.
The initial suspicion was, as in the first case, soft tissue
infection or deep venous thrombosis. He was treated
with cefuroxime 1500 q.8.h. and given dalterapin. Fluid
treatment with isotonic saline normalised the blood
pressure. The orthopaedic surgeon was consulted on the
suspicion of compartment syndrome, on which no basis
was found.
Figure 2 CT abdomen (patient 1), pelvic level, where the
severely oedematous peritoneum and mesentery are filling the
abdominal cavity.
Figure 3 CT abdomen (patient 1), sagittal view with contrast, again illustrating what is seen as mucous masses filling the abdominal
cavity, but which by ultrasonographic examination was revealed as massively thickened peritoneum.
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Day 2
The following day the patient was able to communicate
that he had injected brown heroin in his right arm. He
was not able to specify when he had injected the
substance.
An ultrasonographic examination of the arm showed
no sign of thrombosis, but as in the first case, diffuse
soft tissue swelling was seen. The patient’s blood
culture showed growth of gram-positive rods and on
suspicion of infection with Bacillus anthracis the
patient was started on intravenous treatment with
meropenem 2 g q.8.h., metronidazole 500 mg q.8.h.
and moxifloxacine 400 mg q.d.. Moxifloxacine was
chosen to ensure as broad-spectrum coverage as pos-
sible until confirmed microbiological identification. He
was admitted to the Infectious Diseases department for
further treatment.
Day 3 – 10
The swelling of the right arm progressed to involve most
of the body. His blood pressure was fluctuating with epi-
sodes of systolic blood pressure dropping to 60 mmHg,
however kidney function was preserved and fluid treat-
ment with crystalloid and albumin was sufficient to
stabilize the blood pressure. At day 7, treatment with
hydroxychloroquine 500 mg q.d. was initiated, followed
by 250 mg q.d. every third day for a total of 7 days in an
attempt to inhibit the effect of the B. anthracis toxins.
As the alanine aminotransferase levels and Inter-
national normalised ratio (INR) were increasing, the
antibiotic treatment was changed to clindamycin 600 mg
q.8.h. and ciprofloxacin 400 mg q.12.h.. On day 9, ex-
tended susceptibility testing of B. anthracis showed sen-
sitivity to penicillin, so antibiotic treatment was changed
to benzyl penicillin 1200 mg q.4.h. and ciprofloxacin 400
mg q.12.h.
Day 11 – 29
The patient’s condition improved rapidly and the blood
pressure stabilised. He received intravenous antibiotic
treatment for 17 days, followed by 4 days treatment with
amoxicillin-clavulanate pills. The patient’s main problem
during this period was the substantial oedema. At day 15
he weighed 108 kg, which was 40 kg more than his
habitual weight. The following days he was treated
with compression bandages. The patient continued to
improve and when discharged on day 29 his weight was
normalised.
Standard infection control precautions were applied in
both cases. Patients were placed in singe rooms and
health care staff used gloves and gowns. In case 1 stand-
ard surgical masks were used.
Laboratory analysis
Patient no. 1
Bacillus anthracis was found in both aerobic blood cul-
ture (Becton Dickinson, Heidelberg; Germany) and in
culture from ascites fluids on a 5 per cent horse blood
agar after 22 to 24 hours of incubation at 35°C. Phase-
contrast microscopy showed large non-motile bacilli and
Gram stain revealed non-branching gram-positive bacilli
growing in chains (Figure 4).
On subcultures the bacilli were without haemolysis
and were lipase negative on egg yolk agar. Matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (Bruker Daltonics, Bremen, Germany) was
performed. The patient history led to analysis with the
Bruker database for security-relevant organisms. The or-
ganism was correctly identified as Bacillus anthracis.
From the blood the score value for best match organism
was 2.568 un-extracted and 2.335 with formic acid ex-
traction. From ascites the un-extracted score was 2.324.
Susceptibility testing was performed. The minimal
inhibitory concentrations (Etest, AB bioMérieux, Solna,
Sweden) were azithromycin = 2.0 μg/mL, ciprofloxacin =
0.047 μg/mL, clindamycin = 0.5 μg/mL, meropenem =
0.064 μg/mL and penicillin = 0.094 μg/mL.
A relative of the patient confirmed that the heroin was
bought locally in Copenhagen and handed in samples of
the remaining heroin. The samples of heroin were
analysed at the National Centre for Biological Defence,
Statens Serum Institute, but B. anthracis spores were
not detected (5).
Patient no. 2
Large non-motile gram-positive bacilli arranged end to
end in chains were found in the aerobic blood cultures
Figure 4 Gram stain of B. anthracis, showing large gram-
positive rods with sub terminal ellipsoidal spores in blood
culture from patient 1.
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(BacT/ALERT, bioMérieux, France). Both culture and
PCR for B. anthracis from the wound were negative.
The isolate was sent the National Reference Labora-
tory, Statens Serum Institute. Susceptibility testing was
performed using disk diffusion test. The isolate was sus-
ceptible to meropenem, penicillin, clindamycin, vanco-
mycin, tetracycline, ciprofloxacin and moxifloxacin, but
resistant to rifampicin. The minimal inhibitory concen-
tration for penicillin was 0.064 μg/mL.
Isolates from both cases were sent to the Robert Koch
Institute in Berlin. A TaqMan based multiplex qPCR for
B. anthracis was performed. All three chromosomal
markers, pag (pXO1), capB (pXO2) and rpoB were
detected by the PCR. In addition the chromosomal
marker dhp61 was found after DNA isolation. Compara-
tive molecular typing with a high resolution 31 marker
multilocus variable-number tandem repeat analysis
(MLVA) and a broad single nucleotide polymorphism
(SNP) analysis revealed that the isolates were identical to
the B. anthracis isolates from earlier outbreaks among
injection drug users [7]. For patient no. 2, an ELISA for
B. anthracis antibodies on a serum sample was negative
although the titer was higher than the control.
Discussion
In this article we describe the first two cases of
injectional anthrax in Denmark. They both presented
with marked pain and oedema of the affected tissue,
which is consistent with earlier descriptions in literature
[5,8]. The molecular typing of these two bacterial iso-
lates has recently been described by Grunow et al. [7].
The first patient presented with pain in the thigh and
abdomen and with rapid progression to systemic in-
volvement. He died on day 4. The second patient, who
presented with fever and a swollen arm, developed a
generalised oedema of approximately 40 kg and although
he initially was septic with low systolic blood pressure
and affected mental status, he responded well to the
given treatment and was discharged after 29 days of
hospitalisation. These two cases illustrate how essential
it is to start antibiotic therapy promptly. Both patients
presented with similar symptoms. However, the first pa-
tient did not receive relevant antibiotic treatment until
24 hours after the symptoms appeared and by that stage,
the infection had progressed into intractable septic
shock, whereas in the second patient antibiotic treat-
ment was initiated early, and his symptoms were halted
and he was managed entirely outside the intensive care
environment.
The first patient had unusual gastrointestinal find-
ings, very similar to one previous published case [9].
Initially, after the first computed tomography (CT)
scan, the radiologists described the findings as large
amounts of ascites or mucus masses. Abdominal
ultrasound examination later revealed that the findings
represented thickened peritoneum and an oedematous
and distended mesentery. Gastrointestinal symptoms
have been described to predominate in some cases of
injectional anthrax and are probably reflecting dissem-
inated disease. In Scotland, abdominal pain was noted
in 46% of confirmed and 17% of probable cases.
Despite the abdominal symptoms, the patient was
afebrile and hemodynamically stable at admission,
which is in line with another reported case by Powell
et al. [10], but within less than 24 hours he collapsed
in cardiac arrest. Very rapid deterioration has been
noted in several previously described cases, and it is
well known that patients with systemic disease have a
very poor prognosis [1].
The main virulence factors of Bacillus anthracis are
the two toxins: Lethal Toxin (LeTx) and Edema toxin
(ETx). They are both binary proteins coupled with a pro-
tective antigen and are implicated in the pathogenesis of
shock and rapid cell-death [11]. There are still questions
left to answer regarding the underlying mechanism of
the toxins [12,13]. Lawrence et al. [14] showed in a
rabbit model that the lethal toxin (LeTx) might have
direct cardiotoxic effects and it is possible that toxins
caused the early cardiac arrest in the first patient. Anti-
toxin therapies are under investigation and are considered
experimental [15]. Chloroquine is known to interfere with
the lysosomale processing of LeTx [16] and chloroquine
has been shown to have a positive effect on the survival of
mammalian cells in vitro as well as in experimental studies
of mice injected with LeTx [17]. The second patient was
treated with chloroquine with a possible positive effect, but
the treatment is experimental and further studies are
needed.
It is generally agreed that patients with septic shock
from Bacillus anthracis should be treated with aggres-
sive hemodynamic support [1] and the patient in the
first case was indeed treated with large amounts of intra-
venous crystalloid solution as well as noradrenalin due
to circulatory failure. However, experimental animal
studies indicate that aggressive fluid therapy can be less
beneficial in anthrax [18] and in rats exposed to LeTx,
noradrenalin increases the blood pressure but does not
enhance survival [19]. It is possible that a more re-
strained fluid approach would have been useful. It was
noteworthy how rapid the abdominal compartment
syndrome progressed during the first hours after ICU
admission and there was actually an initial positive re-
sponse with a decrease of intra-abdominal pressure after
starting the continuous veno-venous hemodiafiltration
(CVVHDF ). The patient tolerated fluid removal through
hemofiltration surprisingly well and his condition actu-
ally briefly improved. In the latter stages of anthrax
treated with relevant antibiotics, disease progression is
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mediated by the effects of the toxins. Due to the size of
anthrax toxins, removal through dialysis is not possible.
Epidemiological evidence implicating heroin as the
vehicle for spore transmission during the Scottish out-
break was very strong. Our case together with the re-
cent cases in Germany, Great Britain and France
suggest that contaminated heroin may be a continuous
source of anthrax in Western Europe leading to both
outbreaks and sporadic cases. It is assumed that the
contamination with anthrax spores occurs during
transportation from Afghanistan through Turkey to
Western Europe and it has been speculated that the
contamination might be through contact with goat-
skins or bonemeal [20]. No Bacillus anthracis spores
were detected in the samples of heroin that were
handed in by the patient’s relative. This is similar to
the Scottish outbreak, where investigators also failed to
detect anthrax in collected heroin samples [5], indicat-
ing that the concentration of spores in the heroin was
very low.
Conclusion
In conclusion, clinicians and clinical microbiologists
need to stay vigilant and suspect anthrax in heroin drug
users presenting with soft tissue infection as well as
systemic infection and sepsis. As our second case illus-
trates injectional anthrax can be successfully treated with
antibiotics, especially if treatment is commenced before
development of severe systemic involvement. Once Bacillus
anthracis infection has developed into septic shock it
should be treated aggressively with hemodynamic and ven-
tilator support.
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